Neutrophils trigger a NF-ΚB dependent polarization of tumorsupportive stromal cells in germinal center B-cell lymphomas

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16471-16487

  Grégoire, Murielle ^a,b,c   Guilloton, Fabien ^a,b,c   Pangault, Céline ^a,b,c,d   Mourcin, Frédéric ^a,b,c   Sok, Phaktra ^a,b,c,d   Latour, Maelle ^c,d   Amé Thomas, Patricia ^a,b,c,d   Flecher, Erwan ^d   Fest, Thierry ^a,b,c,d   Tarte, Karin ^a,b,c,d  

^a INSERM   (France)

^b UNIVERSITÉ DE RENNES 1   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

B cell lymphoma; Cell differentiation; Cell interaction; Lymph node; Tumor microenvironment

Indexed keywords

APRIL PROTEIN; B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTAGLANDIN E2; CCL2 PROTEIN, HUMAN; I KAPPA B KINASE; IL8 PROTEIN, HUMAN; TNFSF13B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; APOPTOSIS; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; CELL INTERACTION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EXTRACELLULAR TRAP; FOLLICULAR LYMPHOMA; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LARGE CELL LYMPHOMA; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; POLARIZATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INDUCTION; STROMA CELL; UPREGULATION; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL MOTION; CHILD; DIFFUSE LARGE B CELL LYMPHOMA; FIBROBLAST; GERMINAL CENTER; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ADULT; APOPTOSIS; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINE CCL2; CHILD; EXTRACELLULAR TRAPS; FIBROBLASTS; GERMINAL CENTER; HUMANS; I-KAPPA B KINASE; INTERLEUKIN-8; LYMPHOMA, FOLLICULAR; LYMPHOMA, LARGE B-CELL, DIFFUSE; NEUTROPHIL INFILTRATION; NEUTROPHILS; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; STROMAL CELLS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84937887017     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4106     Document Type: Article

References (53)

1. Mantovani A, Cassatella MA, Costantini C and Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature reviews Immunology. 2011; 11:519-531.
2. Scapini P and Cassatella MA. Social networking of human neutrophils within the immune system. Blood. 2014; 124:710-719.
3. Sionov RV, Fridlender ZG and Granot Z. The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment. Cancer microenvironment: official journal of the International Cancer Microenvironment Society. 2014.
4. Sparmann A and Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer cell. 2004; 6:447-458.
5. Dumitru CA, Fechner MK, Hoffmann TK, Lang S and Brandau S. A novel p38-MAPK signaling axis modulates neutrophil biology in head and neck cancer. Journal of leukocyte biology. 2012; 91:591-598.
6. Ohlund D, Elyada E and Tuveson D. Fibroblast heterogeneity in the cancer wound. The Journal of experimental medicine. 2014; 211:1503-1523.
7. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L and Pistoia V. Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells. 2008; 26:151-162.
8. Cassatella MA, Mosna F, Micheletti A, Lisi V, Tamassia N, Cont C, Calzetti F, Pelletier M, Pizzolo G and Krampera M. Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. Stem Cells. 2011; 29:1001-1011.
9. Zhu Q, Zhang X, Zhang L, Li W, Wu H, Yuan X, Mao F, Wang M, Zhu W, Qian H and Xu W. The IL-6-STAT3 axis mediates a reciprocal crosstalk between cancer-derived mesenchymal stem cells and neutrophils to synergistically prompt gastric cancer progression. Cell death & disease. 2014; 5:e1295.
10. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadie M, Simonetti A, Lutz JM and Berrino F. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010; 116:3724-3734.
11. Guilloton F, Caron G, Menard C, Pangault C, Ame- Thomas P, Dulong J, De Vos J, Rossille D, Henry C, Lamy T, Fouquet O, Fest T and Tarte K. Mesenchymal stromal cells orchestrate follicular lymphoma cell niche through the CCL2-dependent recruitment and polarization of monocytes. Blood. 2012; 119:2556-2567.
12. Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, Weisenburger DD, Lynch JC, Vose J, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England journal of medicine. 2004; 351:2159-2169.
13. Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, et al. Stromal gene signatures in large-B-cell lymphomas. The New England journal of medicine. 2008; 359:2313-2323.
14. Ame-Thomas P and Tarte K. The yin and the yang of follicular lymphoma cell niches: role of microenvironment heterogeneity and plasticity. Seminars in cancer biology. 2014; 24:23-32.
15. Scott DW and Gascoyne RD. The tumour microenvironment in B cell lymphomas. Nature reviews Cancer. 2014; 14:517-534.
16. Mourcin F, Pangault C, Amin-Ali R, Ame-Thomas P and Tarte K. Stromal cell contribution to human follicular lymphoma pathogenesis. Frontiers in immunology. 2012; 3:280.
17. Ame-Thomas P, Maby-El Hajjami H, Monvoisin C, Jean R, Monnier D, Caulet-Maugendre S, Guillaudeux T, Lamy T, Fest T and Tarte K. Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood. 2007; 109:693-702.
18. Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC, Sotomayor E, Dalton WS and Tao J. Lymphoma cell adhesion-induced expression of B cellactivating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia. 2009; 23:170-177.
19. He B, Chadburn A, Jou E, Schattner EJ, Knowles DM and Cerutti A. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL. J Immunol. 2004; 172:3268-3279.
20. Gupta M, Dillon SR, Ziesmer SC, Feldman AL, Witzig TE, Ansell SM, Cerhan JR and Novak AJ. A proliferationinducing ligand mediates follicular lymphoma B-cell proliferation and cyclin D1 expression through phosphatidylinositol 3-kinase-regulated mammalian target of rapamycin activation. Blood. 2009; 113:5206-5216.
21. Scapini P, Bazzoni F and Cassatella MA. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunology letters. 2008; 116:1-6.
22. Holden NJ, Williams JM, Morgan MD, Challa A, Gordon J, Pepper RJ, Salama AD, Harper L and Savage CO. ANCAstimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular process. Annals of the rheumatic diseases. 2011; 70:2229-2233.
23. Puga I, Cols M, Barra CM, He B, Cassis L, Gentile M, Comerma L, Chorny A, Shan M, Xu W, Magri G, Knowles DM, Tam W, Chiu A, Bussel JB, Serrano S, et al. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature immunology. 2012; 13:170-180.
24. Nagelkerke SQ, aan de Kerk DJ, Jansen MH, van den Berg TK and Kuijpers TW. Failure to detect functional neutrophil B helper cells in the human spleen. PloS one. 2014; 9:e88377.
25. Gorlino CV, Ranocchia RP, Harman MF, Garcia IA, Crespo MI, Moron G, Maletto BA and Pistoresi-Palencia MC. Neutrophils exhibit differential requirements for homing molecules in their lymphatic and blood trafficking into draining lymph nodes. J Immunol. 2014; 193:1966-1974.
26. Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry ML, Magistrelli G, Masternak K, Chevailler A, Delneste Y and Jeannin P. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood. 2011; 117:1196-1204.
27. Schwaller J, Schneider P, Mhawech-Fauceglia P, McKee T, Myit S, Matthes T, Tschopp J, Donze O, Le Gal FA and Huard B. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood. 2007; 109:331-338.
28. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN and Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. American journal of hematology. 2010; 85:896-899.
29. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403:503-511.
30. Cremasco V, WoodruffMC, Onder L, Cupovic J, Nieves- Bonilla JM, Schildberg FA, Chang J, Cremasco F, Harvey CJ, Wucherpfennig K, Ludewig B, Carroll MC and Turley SJ. B cell homeostasis and follicle confines are governed by fibroblastic reticular cells. Nature immunology. 2014; 15:973-981.
31. Kim J, Lee S, Kim YM, Jeoung DI and Choe J. Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins. Molecular immunology. 2013; 55:418-423.
32. Sangaletti S, Tripodo C, Vitali C, Portararo P, Guarnotta C, Casalini P, Cappetti B, Miotti S, Pinciroli P, Fuligni F, Fais F, Piccaluga PP and Colombo MP. Defective stromal remodeling and neutrophil extracellular traps in lymphoid tissues favor the transition from autoimmunity to lymphoma. Cancer discovery. 2014; 4:110-129.
33. Guadagnoli M, Kimberley FC, Phan U, Cameron K, Vink PM, Rodermond H, Eldering E, Kater AP, van Eenennaam H and Medema JP. Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood. 2011; 117:6856-6865.
34. Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, Yin XY and Zheng L. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. Journal of hepatology. 2011; 54:948-955.
35. Gallouet AS, Travert M, Bresson-Bepoldin L, Guilloton F, Pangault C, Caulet-Maugendre S, Lamy T, Tarte K and Guillaudeux T. COX-2-independent effects of celecoxib sensitize lymphoma B cells to TRAIL-mediated apoptosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20:2663-2673.
36. Katakai T, Hara T, Sugai M, Gonda H and Shimizu A. Lymph node fibroblastic reticular cells construct the stromal reticulum via contact with lymphocytes. The Journal of experimental medicine. 2004; 200:783-795.
37. Koning JJ and Mebius RE. Interdependence of stromal and immune cells for lymph node function. Trends in immunology. 2012; 33:264-270.
38. Franco G, Guarnotta C, Frossi B, Piccaluga PP, Boveri E, Gulino A, Fuligni F, Rigoni A, Porcasi R, Buffa S, Betto E, Florena AM, Franco V, Iannitto E, Arcaini L, Pileri SA, et al. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma. Blood. 2014; 123:1836-1849.
39. Maugeri N, Campana L, Gavina M, Covino C, De Metrio M, Panciroli C, Maiuri L, Maseri A, D'Angelo A, Bianchi ME, Rovere-Querini P and Manfredi AA. Activated platelets present High Mobility Group Box 1 to neutrophils, inducing autophagy and promoting the extrusion of neutrophil extracellular traps. J Thromb Haemost. 2014; 12:2074-88.
40. Epron G, Ame-Thomas P, Le Priol J, Pangault C, Dulong J, Lamy T, Fest T and Tarte K. Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling. Leukemia. 2012; 26:139-148.
41. Mueller CG, Boix C, Kwan WH, Daussy C, Fournier E, Fridman WH and Molina TJ. Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. Journal of leukocyte biology. 2007; 82:567-575.
42. Alvaro T, Lejeune M, Camacho FI, Salvado MT, Sanchez L, Garcia JF, Lopez C, Jaen J, Bosch R, Pons LE, Bellas C and Piris MA. The presence of STAT1-positive tumorassociated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006; 91:1605-1612.
43. Hu X, Park-Min KH, Ho HH and Ivashkiv LB. IFN-gammaprimed macrophages exhibit increased CCR2-dependent migration and altered IFN-gamma responses mediated by Stat1. J Immunol. 2005; 175:3637-3647.
44. Yang EJ, Choi E, Ko J, Kim DH, Lee JS and Kim IS. Differential effect of CCL2 on constitutive neutrophil apoptosis between normal and asthmatic subjects. Journal of cellular physiology. 2012; 227:2567-2577.
45. Yang ZZ, Grote DM, Xiu B, Ziesmer SC, Price-Troska TL, Hodge LS, Yates DM, Novak AJ and Ansell SM. TGFbeta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin's lymphoma. Leukemia. 2014; 28:1872-1884.
46. Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E and Czuczman MS. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clinical cancer research: an official journal of the American Association for Cancer Research. 2003; 9:5866-5873.
47. Golay J, Da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, Klein C and Introna M. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013; 122:3482-3491.
48. Pascal V, Laffleur B, Debin A, Cuvillier A, van Egmond M, Drocourt D, Imbertie L, Pangault C, Tarte K, Tiraby G and Cogne M. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells. Haematologica. 2012; 97:1686-1694.
49. Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouille V, Quittet P, Klein B and Rossi JF. Granulocytemacrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26:2725-2731.
50. van der Kolk LE, Grillo-Lopez AJ, Baars JW and van Oers MH. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. Leukemia. 2003; 17:1658-1664.
51. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004; 103:275-282.
52. Tattevin P, Monnier D, Tribut O, Dulong J, Bescher N, Mourcin F, Uhel F, Le Tulzo Y and Tarte K. Enhanced indoleamine 2,3-dioxygenase activity in patients with severe sepsis and septic shock. The Journal of infectious diseases. 2010; 201:956-966.
53. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, Bertoni F, Ponzoni M, Scandurra M, Califano A, Bhagat G, Chadburn A, Dalla-Favera R and Pasqualucci L. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459:717-721.